Xeris Biopharma Achieves First Net Income, Reports Strong Revenue Growth, and Advances Key Pipeline Asset

summarizeSummary

Xeris Biopharma reported its first net income in 2025, with strong revenue growth and positive operating cash flow, while advancing a key pipeline asset and navigating patent litigation for its lead product.

check_boxKey Events

• First-Ever Net Income Achieved

  Xeris Biopharma reported net income of $0.6 million for the fiscal year ended December 31, 2025, marking its first profitable year since inception, a significant improvement from net losses of $54.8 million in 2024.

• Strong Revenue Growth

  Total revenue increased by 43.7% to $291.8 million in 2025 from $203.1 million in 2024, primarily driven by a 116.7% increase in Recorlev net revenue due to higher patient demand.

• Positive Operating Cash Flow

  The company generated $28.6 million in net cash from operating activities for the year ended December 31, 2025, a substantial turnaround from using $37.0 million in 2024.

• XP-8121 Pipeline Advances to Phase 3

  The XP-8121 (once-weekly subcutaneous levothyroxine) product candidate is now Phase 3-ready, with a clinical trial planned for 2026, targeting a substantial estimated market opportunity of $1.0 to $3.0 billion in peak net sales.

auto_awesomeAnalysis

Xeris Biopharma Holdings, Inc. reported its first-ever net income of $0.6 million for the fiscal year ended December 31, 2025, a significant turnaround from prior losses. This financial improvement was driven by robust product revenue growth, particularly from Recorlev, and a shift to positive operating cash flow. The company also advanced its XP-8121 pipeline candidate to Phase 3, with a clinical trial planned for 2026. While the company is engaged in patent infringement litigation for Recorlev, the filing of the lawsuit triggered a 30-month stay on generic FDA approval, providing temporary market exclusivity. Investors should monitor the outcome of this litigation and the commercialization progress of XP-8121.